Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data
- PMID:27567804
- DOI: 10.3233/JAD-151006
Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims Data
Abstract
Background: While acute detrimental effects of benzodiazepine (BDZ), and BDZ and related z-substance (BDZR) use on cognition and memory are known, the association of BDZR use and risk of dementia in the elderly is controversially discussed. Previous studies on cohort or claims data mostly show an increased risk for dementia with the use of BDZs or BDZRs. For Germany, analyses on large population-based data sets are missing.
Objective: To evaluate the association between regular BDZR use and incident any dementia in a large German claims data set.
Methods: Using longitudinal German public health insurance data from 2004 to 2011 we analyzed the association between regular BDZR use (versus no BDZR use) and incident dementia in a case-control design. We examined patient samples aged≥60 years that were free of dementia at baseline. To address potential protopathic bias we introduced a lag time between BDZR prescription and dementia diagnosis. Odds ratios were calculated applying conditional logistic regression, adjusted for potential confounding factors such as comorbidities and polypharmacy.
Results: The regular use of BDZRs was associated with a significant increased risk of incident dementia for patients aged≥60 years (adjusted odds ratio [OR] 1.21, 95% confidence interval [CI] 1.13-1.29). The association was slightly stronger for long-acting substances than for short-acting ones. A trend for increased risk for dementia with higher exposure was observed.
Conclusion: The restricted use of BDZRs may contribute to dementia prevention in the elderly.
Keywords: Benzodiazepines; dementia; elderly; risk factor; z-substances.
Similar articles
- A Systematic Review and Meta-Analysis of the Risk of Dementia Associated with Benzodiazepine Use, After Controlling for Protopathic Bias.Penninkilampi R, Eslick GD.Penninkilampi R, et al.CNS Drugs. 2018 Jun;32(6):485-497. doi: 10.1007/s40263-018-0535-3.CNS Drugs. 2018.PMID:29926372
- Use of Antiepileptic Drugs and Dementia Risk-an Analysis of Finnish Health Register and German Health Insurance Data.Taipale H, Gomm W, Broich K, Maier W, Tolppanen AM, Tanskanen A, Tiihonen J, Hartikainen S, Haenisch B.Taipale H, et al.J Am Geriatr Soc. 2018 Jul;66(6):1123-1129. doi: 10.1111/jgs.15358. Epub 2018 Mar 22.J Am Geriatr Soc. 2018.PMID:29566430
- Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD.Dyer AH, Murphy C, Lawlor B, Kennelly SP; NILVAD Study Group.Dyer AH, et al.J Am Med Dir Assoc. 2020 Feb;21(2):194-200. doi: 10.1016/j.jamda.2019.08.006. Epub 2019 Oct 8.J Am Med Dir Assoc. 2020.PMID:31604674Clinical Trial.
- Benzodiazepine use and cognitive decline in the elderly.Picton JD, Marino AB, Nealy KL.Picton JD, et al.Am J Health Syst Pharm. 2018 Jan 1;75(1):e6-e12. doi: 10.2146/ajhp160381.Am J Health Syst Pharm. 2018.PMID:29273607Review.
- Use of sedative-hypnotic medications and risk of dementia: A systematic review and meta-analysis.AlDawsari A, Bushell TJ, Abutheraa N, Sakata S, Al Hussain S, Kurdi A.AlDawsari A, et al.Br J Clin Pharmacol. 2022 Feb;88(4):1567-1589. doi: 10.1111/bcp.15113. Epub 2021 Nov 11.Br J Clin Pharmacol. 2022.PMID:34679196Review.
Cited by
- The association between benzodiazepine use and greater risk of neurocognitive impairment is moderated by medical burden in people with HIV.Sundermann EE, Saloner R, Rubtsova A, Nguyen AL, Letendre S, Moore RC, Cherner M, Ma Q, Marquine MJ.Sundermann EE, et al.J Neurovirol. 2022 Jun;28(3):410-421. doi: 10.1007/s13365-022-01076-1. Epub 2022 Apr 7.J Neurovirol. 2022.PMID:35389174Free PMC article.
- Promoting Successful Cognitive Aging: A Ten-Year Update.Krivanek TJ, Gale SA, McFeeley BM, Nicastri CM, Daffner KR.Krivanek TJ, et al.J Alzheimers Dis. 2021;81(3):871-920. doi: 10.3233/JAD-201462.J Alzheimers Dis. 2021.PMID:33935078Free PMC article.Review.
- Impact of benzodiazepine consumption reduction on future burden of dementia.Jacqmin-Gadda H, Guillet F, Mathieu C, Helmer C, Pariente A, Joly P.Jacqmin-Gadda H, et al.Sci Rep. 2020 Sep 4;10(1):14666. doi: 10.1038/s41598-020-71482-0.Sci Rep. 2020.PMID:32887900Free PMC article.
- The Impact of Antipsychotic Drugs on Long-term Care, Nursing Home Admission, and Death in Dementia Patients.Nerius M, Johnell K, Garcia-Ptacek S, Eriksdotter M, Haenisch B, Doblhammer G.Nerius M, et al.J Gerontol A Biol Sci Med Sci. 2018 Sep 11;73(10):1396-1402. doi: 10.1093/gerona/glx239.J Gerontol A Biol Sci Med Sci. 2018.PMID:29228107Free PMC article.
- A Systematic Review and Meta-Analysis of the Risk of Dementia Associated with Benzodiazepine Use, After Controlling for Protopathic Bias.Penninkilampi R, Eslick GD.Penninkilampi R, et al.CNS Drugs. 2018 Jun;32(6):485-497. doi: 10.1007/s40263-018-0535-3.CNS Drugs. 2018.PMID:29926372
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical